StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca Soliris (eculizumab) — Worldwide product sales by Quarter

Soliris (eculizumab) — Worldwide product sales ($M) ($M)

QuarterlyAnnual

AstraZeneca Soliris (eculizumab) — Worldwide product sales: $389M in Q2 2026, down 26.6% from a year earlier. That is the lowest of the 20 quarters on record here.

Latest, Q2 2026
389
Period ended Jun 30, 2026
Change on a year earlier
-26.6%
530 in Q2 2025
History
20 quarters
Since Q3 2021
Sources
20
Documents cited below

Where the Q2 2026 figure comes from

“|| Soliris | 389 | | ( 27 ) | | ( 28 ) | | 199 | | ( 29 ) | | 135 | | ( 15 ) | | ( 19 ) | | 28 | | ( 50 ) | | ( 50 ) | | 27 | | ( 21 ) | | ( 22 )”

Source: Form 6-K FY2026Q2 Earnings Release ↗

Reported in Form 6-K Quarterly & Form 20-F Product Sales by Medicine & Region Tables.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedSoliris (eculizumab) — Worldwide product sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026389-26.6%Form 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 2026389-12.4%Form 6-K FY2026Q1 Earnings Release ↗
Q4 2025Dec 31, 2025401-26.2%Form 6-K FY2025Q4 Earnings Release ↗
Q3 2025Sep 30, 2025462-23.8%Form 6-K FY2025Q3 Earnings Release ↗
Q2 2025Jun 30, 2025530-24.3%Form 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 2025444-39.9%Form 6-K FY2025Q1 Earnings Release ↗
Q4 2024Dec 31, 2024543-24.1%Form 6-K FY2024Q4 Earnings Release ↗
Q3 2024Sep 30, 2024606-22.4%Form 6-K FY2024Q3 Earnings Release ↗
Q2 2024Jun 30, 2024700-14.0%Form 6-K FY2024Q2 Earnings Release ↗
Q1 2024Mar 31, 2024739-11.4%Form 6-K FY2024Q1 Earnings Release ↗
Q4 2023Dec 31, 2023715-15.3%Form 6-K FY2023Q4 Earnings Release ↗
Q3 2023Sep 30, 2023781-13.3%Form 6-K FY2023Q3 Earnings Release ↗
Q2 2023Jun 30, 2023814-20.7%Form 6-K FY2023Q2 Earnings Release ↗
Q1 2023Mar 31, 2023834-15.8%Form 6-K FY2023Q1 Earnings Release ↗
Q4 2022Dec 31, 2022844-21.6%Form 6-K FY2022Q4 Earnings Release ↗
Q3 2022Sep 30, 2022901+12.9%Form 6-K FY2022Q3 Earnings Release ↗

Breakdown

What makes up soliris (eculizumab) — Worldwide product sales

Cite this data

StockData. (2026). AstraZeneca Soliris (eculizumab) — Worldwide product sales ($M), quarterly Q3 2021–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-soliris-world

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.